<DOC>
	<DOCNO>NCT01917383</DOCNO>
	<brief_summary>The purpose study evaluate intraocular pressure ( IOP ) lower efficacy safety tolerability profile trabodenoson ophthalmic formulation compare timolol maleate ophthalmic solution 0.5 % adult ocular hypertension ( OHT ) primary open-angle glaucoma ( POAG ) already receive treatment latanoprost ophthalmic solution 0.005 % every evening ( QPM ) .</brief_summary>
	<brief_title>A Phase II Study Evaluate Additivity Trabodenoson Latanoprost Adults With Ocular Hypertension Primary Open-Angle Glaucoma</brief_title>
	<detailed_description>Criteria Inclusion Criteria : 1 . Subject sign dated current inform consent form ( ICF ) . 2 . Subject diagnosis ocular hypertension ( OHT ) primary open-angle glaucoma ( POAG ) ( exclude secondary , pseudo-exfoliation , pigment dispersion glaucoma ) . 3 . Aged 18 old . 4 . Mean intraocular pressure ( IOP ) ≥24 ≤34 mm Hg . Exclusion Criteria : 1 . No significant visual field loss new field loss within past year . 2 . Cup-to-disc ratio ≥0.8 3 . Central corneal thickness &lt; 500 µm &gt; 600 µm 4 . A recent ( acute ) chronic medical condition might obfuscate Subject 's study data</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Subject sign dated current inform consent form ( ICF ) . 2 . Subject diagnosis ocular hypertension ( OHT ) primary openangle glaucoma ( POAG ) ( exclude secondary , pseudoexfoliation , pigment dispersion glaucoma ) . 3 . Aged 18 old . 4 . Mean intraocular pressure ( IOP ) ≥24 ≤34 mm Hg . 1 . No significant visual field loss new field loss within past year . 2 . Cuptodisc ratio ≥0.8 3 . Central corneal thickness &lt; 500 µm &gt; 600 µm 4 . A recent ( acute ) chronic medical condition might obfuscate Subject 's study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>primary open angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>adenosine agonist</keyword>
	<keyword>eye drop</keyword>
	<keyword>trabodenoson</keyword>
	<keyword>trabecular meshwork</keyword>
</DOC>